Department of Dermatology, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Spain.
Department of Dermatology, Consorci Sanitari de Terrassa, Carretera Torrebonica, s/n, 08227, Terrassa, Spain.
Photodiagnosis Photodyn Ther. 2021 Jun;34:102339. doi: 10.1016/j.pdpdt.2021.102339. Epub 2021 May 14.
The successful treatment of hidradenitis suppurativa (HS) with intralesional photodynamic therapy (IL-PDT) has been previously reported in some case series published a few years ago. We present additional data and patient outcome for this form of PDT.
This is an observational retrospective study including all patients diagnosed with HS and treated with IL-PDT in the Hospital Universitari Son Espases from February 2019 to February 2020. Under local or general anesthesia, 5-aminolevulinic acid (5ALA) in gel 2 % or solution 1 % was introduced in the lesion. After two hours, the lesion was intralesionally irradiated (1.4 W, fluence 168 J/cm2) with the tip of a 0.4-mm thick optical fiber connected to a continuous 630-nm diode laser. The main outcome variable was the result (remission, improvement or no change) for each lesion 3 months after the therapy. The result at 6 months and the side effects were secondary outcomes. A multivariate analysis was carried out in order to obtain adjusted odds ratios for no change vs improvement or remission at 3 months for significant variables.
A total of 117 lesions (28 nodules and 89 fistulae) were treated in 42 patients. At 3 months, 26 lesions (22.2 %) had resolved, 73 (62.4 %) had improved in size or symptoms, and 18 (15.4 %) experienced no change. The most frequent side effects were skin burns (53 lesions, 45.3 %), and abscess formation (8 lesions, 6.8 %). In the multivariate analysis, significant variables for no benefit were: a higher International Hidradenitis Suppurativa (IHS4) score, active smoking and gluteal and inguinal location.
Although our results did not present the level of remission of the previous studies, IL-PDT was useful in most of our patients. Early interventions in patients with lower inflammatory burden were the most valuable.
几年前的一些病例系列研究报告称,腔内光动力疗法(IL-PDT)可成功治疗化脓性汗腺炎(HS)。我们提供了这种 PDT 形式的更多数据和患者结果。
这是一项观察性回顾性研究,纳入了 2019 年 2 月至 2020 年 2 月在 Son Espases 大学医院诊断为 HS 并接受 IL-PDT 治疗的所有患者。在局部或全身麻醉下,将凝胶 2%或溶液 1%的 5-氨基酮戊酸(5ALA)引入病变部位。两小时后,用连接到连续 630nm 二极管激光的 0.4 毫米厚光纤的尖端进行腔内照射(1.4W,剂量 168J/cm2)。主要观察变量为治疗后 3 个月时每个病变的结果(缓解、改善或无变化)。次要观察变量为 6 个月时的结果和副作用。对有统计学意义的变量进行多变量分析,以获得 3 个月时无变化与改善或缓解的调整比值比。
共治疗了 42 名患者的 117 个病变(28 个结节和 89 个瘘管)。3 个月时,26 个病变(22.2%)已缓解,73 个(62.4%)病变大小或症状改善,18 个(15.4%)无变化。最常见的副作用是皮肤灼伤(53 个病变,45.3%)和脓肿形成(8 个病变,6.8%)。多变量分析显示,无获益的显著变量为:更高的国际化脓性汗腺炎评分(IHS4)、吸烟和臀部及腹股沟部位。
尽管我们的结果未达到之前研究的缓解水平,但 IL-PDT 对我们大多数患者仍然有用。对炎症负担较低的患者进行早期干预效果最佳。